Reaction Biology

Across all of our services, we consistently deliver high quality data, innovative solutions for custom-tailored projects, collaboration with scientists, and the flexibility you need to take your drug discovery program from target research to preclinical candidate and beyond. Our goal is the creation of potent drug candidates to meet the needs of tomorrow’s cancer patients. The Reaction Biology Platform offers a broad portfolio of services and a global network of partners that enable us to provide end-to-end service for the discovery of new small molecule and large molecule therapeutics. Reaction Biology brings over 20 years of experience supporting the development of new small molecules and large molecule therapies. We offer a broad portfolio of services that can provide end-to-end solutions for drug discovery, combined with an agile science-focused culture that delivers the same high quality of data for projects of any size. Reaction Biology offers one of the largest portfolio of kinase assays in the industry to support discovery of new kinase inhibitors. Reaction Biology offers a comprehensive portfolio of RAS assay services to support discovery of new RAS inhibitors. Reaction Biology's comprehensive portfolio of in vitro immuno-oncology assays and in vivo tumor models provides scientists with various platforms to test new cancer drug candidate's potency and efficacy.